Granted it’s a Mirror article, but interesting with potentially bad ramifications if true.
Researchers found a middle-aged man who had mild symptoms but a prolonged version of the potentially deadly illness, according to reports.
The first patient who recovered from coronavirus donated plasma on Wednesday that will be used to create a “passive vaccine” to treat Israelis who are severely ill with COVID-19.
This assumes that those who have recovered from COVID-19 have developed special anti-virus proteins or antibodies in their plasma, which could therefore help sick patients cope with the disease.
Defining our “New Normal” in the Age of Coronavirus — Amanda Christensen, ideaXme (http://radioideaxme.com/) guest interviewer, interviews Ben Hammersley, one of the world’s leading futurists to answer questions about how we are going to work, live, thrive, and innovate in the coming years — #Ideaxme #BenHammersley #Innovation #Futurist #Futurism #Covid19 #Coronavirus #Science #Longevity #Health #Medicine #Environment #Space #Oceans #Literature #Music #Food #Future #Entertainment #Sports #Fashion Awesome Foundation European University Institute United Nations Alliance of Civilizations (UNAOC) UNAOC Fellowship Program Goldsmiths, University of London WIRED UK The Brookings Institution European Commission.
Amanda Christensen, ideaXme guest interviewer, interviews Ben Hammersley, one of the world’s leading futurists and founder of international Strategic Foresight agency Hammersley Futures.
Continue reading “Ben Hammersley Futurist, Defines our New Normal in the Age of Coronavirus” »
In yet another demonstration of how rapidly technology can advance, biotech firm Abbott Laboratories has developed a new molecular test for the detection of novel coronavirus (COVID-19), which delivers results in just five minutes.
Abbott Laboratories, headquartered in Illinois, United States, has been granted Emergency Use Authorisation (EUA) by the Food and Drug Administration (FDA) for adapting COVID-19 tests to its ID NOW platform.
Continue reading “New test can detect COVID-19 in just five minutes” »
JERUSALEM (Reuters) — Israel has begun testing a COVID-19 vaccine prototype on rodents at its bio-chemical defense laboratory, a source said on Tuesday.
Prime Minister Benjamin Netanyahu ordered the Israel Institute for Biological Research (IIBR), in rural Ness Ziona, to join the fight against the coronavirus pandemic on Feb. 1, prompting an easing of its secrecy as it cooperates with civilian scientists and private firms.
In a statement, Netanyahu’s office said IIBR director Shmuel Shapira had informed him of “significant progress” in designing a vaccine prototype and that the institute “is now preparing a model for commencing an animal trial”.
Want to receive this post in your inbox every day? Sign up for the Supply Lines newsletter, and follow Bloomberg Economics on Twitter for more.
Three years ago, manufacturing gadgets in China was a given. That’s changed fundamentally in the era of trade wars and coronavirus.
Under the new reality, the world’s electronics makers are actively seeking ways to diversify their supply chains and reduce their dependence on any single country, no matter how attractive.
This Is How Your Immune System Reacts to #Coronavirus: https://bit.ly/3bHkdnv by Dana G Smith Explaining why COVID-19 induces different symptoms on different individuals. #COVID19 #CoronavirusOutbreak
Here’s how the immune system responds when a person catches Covid-19 — and what that means for treatment.
Don’t be stupid be innovative. Keep you, your friends and family safe. Here is a collection of free 3D printable tools that may help in this fight against coronavirus.
Here is a selection of the most useful 3D models to make with a 3D printer agains coronavirus covid-19.
The coronavirus can travel up to 23–27 feet :
This JAMA Insights Clinical Update discusses the need to better understand the dynamics of respiratory disease transmission by better characterizing transmission routes, the role of patient physiology in shaping them, and best approaches for source control in the context of the COVID-19 outbreak.
